BofA Raises Teva Pharmaceutical (TEVA) PT to $24, Amid "Pivot to Growth" Strategy Execution

Teva Pharmaceutical Industries Limited (NYSE:TEVA) is one of the most promising stocks under $100. On October 9, BofA raised the firm’s price target on Teva to $24 from $22, while keeping a Buy rating on the shares. This sentiment was posted as BofA analyzed Q3 2025 drug pricing & sales volume and company comments, and concluded that the firm anticipates no significant Q3 EPS surprises (beats or misses) and no changes to 2026 financial outlooks for the biopharma companies that it covers.

Earlier in Q2 2025, Teva Pharmaceutical marked its 10th consecutive quarter of year-over-year revenue growth as it executes its Pivot to Growth Strategy. The company is targeting a 30% operating profit margin by 2027. Total revenues for the quarter were $4.2 billion, which was an increase of ~1% in local currency when excluding revenues from the Japan Business Venture, which was divested.

Growth was primarily driven by the innovative portfolio, which collectively grew by ~26%. Based on this performance, Teva increased its 2025 revenue outlook for its key innovative products. AUSTEDO revenues were $498 million globally in Q2, up ~19% globally and ~22% in the US, with the 2025 revenue outlook raised to $2,000 to $2,050 million. AJOVY global revenues were $155 million, up ~31%, with the outlook increased to $630 to $640 million. UZEDY revenues were $54 million, accelerating by ~120%, with the outlook raised to $190 to $200 million.

Teva Pharmaceutical Industries Limited (NYSE:TEVA) is a healthcare company that develops, manufactures, markets, and distributes generic and other medicines & biopharmaceutical products.

While we acknowledge the potential of TEVA as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you’re looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock.

READ NEXT: 30 Stocks That Should Double in 3 Years and 11 Hidden AI Stocks to Buy Right Now.

Disclosure: None. This article is originally published at Insider Monkey.